The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Duetact     5-[[4-[2-(5-ethylpyridin-2...

Synonyms: Glustin, Piozone, Actost, Pioglu, Zactos, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of HSDB 7322


Psychiatry related information on HSDB 7322


High impact information on HSDB 7322


Chemical compound and disease context of HSDB 7322


Biological context of HSDB 7322


Anatomical context of HSDB 7322


Associations of HSDB 7322 with other chemical compounds


Gene context of HSDB 7322


Analytical, diagnostic and therapeutic context of HSDB 7322


  1. Effects of the PPARgamma agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus. Nagashima, K., Lopez, C., Donovan, D., Ngai, C., Fontanez, N., Bensadoun, A., Fruchart-Najib, J., Holleran, S., Cohn, J.S., Ramakrishnan, R., Ginsberg, H.N. J. Clin. Invest. (2005) [Pubmed]
  2. Peroxisome proliferator-activated receptor gamma ligands suppress colon carcinogenesis induced by azoxymethane in mice. Osawa, E., Nakajima, A., Wada, K., Ishimine, S., Fujisawa, N., Kawamori, T., Matsuhashi, N., Kadowaki, T., Ochiai, M., Sekihara, H., Nakagama, H. Gastroenterology (2003) [Pubmed]
  3. Pioglitazone prevents alcohol-induced fatty liver in rats through up-regulation of c-Met. Tomita, K., Azuma, T., Kitamura, N., Nishida, J., Tamiya, G., Oka, A., Inokuchi, S., Nishimura, T., Suematsu, M., Ishii, H. Gastroenterology (2004) [Pubmed]
  4. Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor. Tontonoz, P., Singer, S., Forman, B.M., Sarraf, P., Fletcher, J.A., Fletcher, C.D., Brun, R.P., Mueller, E., Altiok, S., Oppenheim, H., Evans, R.M., Spiegelman, B.M. Proc. Natl. Acad. Sci. U.S.A. (1997) [Pubmed]
  5. Pioglitazone treatment increases whole body fat but not total body water in patients with non-alcoholic steatohepatitis. Balas, B., Belfort, R., Harrison, S.A., Darland, C., Finch, J., Schenker, S., Gastaldelli, A., Cusi, K. J. Hepatol. (2007) [Pubmed]
  6. Suppression of N-nitrosobis(2-oxopropyl)amine-induced pancreatic carcinogenesis in hamsters by pioglitazone, a ligand of peroxisome proliferator-activated receptor gamma. Takeuchi, Y., Takahashi, M., Sakano, K., Mutoh, M., Niho, N., Yamamoto, M., Sato, H., Sugimura, T., Wakabayashi, K. Carcinogenesis (2007) [Pubmed]
  7. Pioglitazone does not increase cerebral glucose utilisation in a murine model of Alzheimer's disease and decreases it in wild-type mice. Galea, E., Feinstein, D.L., Lacombe, P. Diabetologia (2006) [Pubmed]
  8. Night-time restricted feeding normalises clock genes and Pai-1 gene expression in the db/db mouse liver. Kudo, T., Akiyama, M., Kuriyama, K., Sudo, M., Moriya, T., Shibata, S. Diabetologia (2004) [Pubmed]
  9. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. Schernthaner, G., Matthews, D.R., Charbonnel, B., Hanefeld, M., Brunetti, P. J. Clin. Endocrinol. Metab. (2004) [Pubmed]
  10. Chronic administration of pioglitazone attenuates intracerebroventricular streptozotocin induced-memory impairment in rats. Pathan, A.R., Viswanad, B., Sonkusare, S.K., Ramarao, P. Life Sci. (2006) [Pubmed]
  11. Effect of pioglitazone treatment on behavioral symptoms in autistic children. Boris, M., Kaiser, C.C., Goldblatt, A., Elice, M.W., Edelson, S.M., Adams, J.B., Feinstein, D.L. Journal of neuroinflammation (2007) [Pubmed]
  12. Blood pressure lowering by pioglitazone. Evidence for a direct vascular effect. Buchanan, T.A., Meehan, W.P., Jeng, Y.Y., Yang, D., Chan, T.M., Nadler, J.L., Scott, S., Rude, R.K., Hsueh, W.A. J. Clin. Invest. (1995) [Pubmed]
  13. Pioglitazone-reduced insulin resistance in patient with Werner syndrome. Imano, E., Kanda, T., Kawamori, R., Kajimoto, Y., Yamasaki, Y. Lancet (1997) [Pubmed]
  14. Nonhypoglycemic effects of thiazolidinediones. Parulkar, A.A., Pendergrass, M.L., Granda-Ayala, R., Lee, T.R., Fonseca, V.A. Ann. Intern. Med. (2001) [Pubmed]
  15. Peroxisome Proliferator-Activated Receptor {gamma} Regulates E-Cadherin Expression and Inhibits Growth and Invasion of Prostate Cancer. Annicotte, J.S., Iankova, I., Miard, S., Fritz, V., Sarruf, D., Abella, A., Berthe, M.L., No??l, D., Pillon, A., Iborra, F., Dubus, P., Maudelonde, T., Culine, S., Fajas, L. Mol. Cell. Biol. (2006) [Pubmed]
  16. Troglitazone induces p27Kip1-associated cell-cycle arrest through down-regulating Skp2 in human hepatoma cells. Koga, H., Harada, M., Ohtsubo, M., Shishido, S., Kumemura, H., Hanada, S., Taniguchi, E., Yamashita, K., Kumashiro, R., Ueno, T., Sata, M. Hepatology (2003) [Pubmed]
  17. Insulin secretory defect in Zucker fa/fa rats is improved by ameliorating insulin resistance. de Souza, C.J., Yu, J.H., Robinson, D.D., Ulrich, R.G., Meglasson, M.D. Diabetes (1995) [Pubmed]
  18. Pioglitazone but not glibenclamide improves cardiac expression of heat shock protein 72 and tolerance against ischemia/reperfusion injury in the heredity insulin-resistant rat. Taniguchi, Y., Ooie, T., Takahashi, N., Shinohara, T., Nakagawa, M., Yonemochi, H., Hara, M., Yoshimatsu, H., Saikawa, T. Diabetes (2006) [Pubmed]
  19. Peroxisome proliferator-activated receptor (PPAR)-alpha activation lowers muscle lipids and improves insulin sensitivity in high fat-fed rats: comparison with PPAR-gamma activation. Ye, J.M., Doyle, P.J., Iglesias, M.A., Watson, D.G., Cooney, G.J., Kraegen, E.W. Diabetes (2001) [Pubmed]
  20. Effects of pioglitazone on fasting and postprandial levels of lipid and hemostatic variables in overweight non-diabetic patients with coronary artery disease. Mieszczanska, H., Kaba, N.K., Francis, C.W., Gerich, J.E., Dodis, R., Schwarz, K.Q., Phipps, R.P., Smith, B.H., Lee, M., Messing, S., Taubman, M.B. J. Thromb. Haemost. (2007) [Pubmed]
  21. Pioglitazone improves the phenotype and molecular defects of a targeted Pkd1 mutant. Muto, S., Aiba, A., Saito, Y., Nakao, K., Nakamura, K., Tomita, K., Kitamura, T., Kurabayashi, M., Nagai, R., Higashihara, E., Harris, P.C., Katsuki, M., Horie, S. Hum. Mol. Genet. (2002) [Pubmed]
  22. Thiazolidenediones mediate apoptosis in prostate cancer cells in part through inhibition of Bcl-xL/Bcl-2 functions independently of PPARgamma. Shiau, C.W., Yang, C.C., Kulp, S.K., Chen, K.F., Chen, C.S., Huang, J.W., Chen, C.S. Cancer Res. (2005) [Pubmed]
  23. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Promrat, K., Lutchman, G., Uwaifo, G.I., Freedman, R.J., Soza, A., Heller, T., Doo, E., Ghany, M., Premkumar, A., Park, Y., Liang, T.J., Yanovski, J.A., Kleiner, D.E., Hoofnagle, J.H. Hepatology (2004) [Pubmed]
  24. Altered Gene Expression Related to Glomerulogenesis and Podocyte Structure in Early Diabetic Nephropathy of db/db Mice and Its Restoration by Pioglitazone. Makino, H., Miyamoto, Y., Sawai, K., Mori, K., Mukoyama, M., Nakao, K., Yoshimasa, Y., Suga, S. Diabetes (2006) [Pubmed]
  25. Peroxisome proliferator-activated receptor-gamma agonists prevent experimental autoimmune encephalomyelitis. Feinstein, D.L., Galea, E., Gavrilyuk, V., Brosnan, C.F., Whitacre, C.C., Dumitrescu-Ozimek, L., Landreth, G.E., Pershadsingh, H.A., Weinberg, G., Heneka, M.T. Ann. Neurol. (2002) [Pubmed]
  26. Effects of pioglitazone on adipose tissue remodeling within the setting of obesity and insulin resistance. de Souza, C.J., Eckhardt, M., Gagen, K., Dong, M., Chen, W., Laurent, D., Burkey, B.F. Diabetes (2001) [Pubmed]
  27. Pioglitazone induces in vivo adipocyte differentiation in the obese Zucker fa/fa rat. Hallakou, S., Doaré, L., Foufelle, F., Kergoat, M., Guerre-Millo, M., Berthault, M.F., Dugail, I., Morin, J., Auwerx, J., Ferré, P. Diabetes (1997) [Pubmed]
  28. Pioglitazone, a peroxisome proliferator-activated receptor gamma agonist, reduces the progression of experimental osteoarthritis in guinea pigs. Kobayashi, T., Notoya, K., Naito, T., Unno, S., Nakamura, A., Martel-Pelletier, J., Pelletier, J.P. Arthritis Rheum. (2005) [Pubmed]
  29. Islet microvasculature in islet hyperplasia and failure in a model of type 2 diabetes. Li, X., Zhang, L., Meshinchi, S., Dias-Leme, C., Raffin, D., Johnson, J.D., Treutelaar, M.K., Burant, C.F. Diabetes (2006) [Pubmed]
  30. Lipin Expression Is Attenuated in Adipose Tissue of Insulin-Resistant Human Subjects and Increases With Peroxisome Proliferator-Activated Receptor {gamma} Activation. Yao-Borengasser, A., Rasouli, N., Varma, V., Miles, L.M., Phanavanh, B., Starks, T.N., Phan, J., Spencer, H.J., McGehee, R.E., Reue, K., Kern, P.A. Diabetes (2006) [Pubmed]
  31. Differential effect of the antidiabetic thiazolidinediones troglitazone and pioglitazone on human platelet aggregation mechanism. Ishizuka, T., Itaya, S., Wada, H., Ishizawa, M., Kimura, M., Kajita, K., Kanoh, Y., Miura, A., Muto, N., Yasuda, K. Diabetes (1998) [Pubmed]
  32. Differential influences of peroxisome proliferator-activated receptors gamma and -alpha on food intake and energy homeostasis. Larsen, P.J., Jensen, P.B., Sørensen, R.V., Larsen, L.K., Vrang, N., Wulff, E.M., Wassermann, K. Diabetes (2003) [Pubmed]
  33. Effects of pioglitazone on suppressor of cytokine signaling 3 expression: potential mechanisms for its effects on insulin sensitivity and adiponectin expression. Kanatani, Y., Usui, I., Ishizuka, K., Bukhari, A., Fujisaka, S., Urakaze, M., Haruta, T., Kishimoto, T., Naka, T., Kobayashi, M. Diabetes (2007) [Pubmed]
  34. Stearoyl-coenzyme A desaturase 1 gene expression increases after pioglitazone treatment and is associated with peroxisomal proliferator-activated receptor-gamma responsiveness. Yao-Borengasser, A., Rassouli, N., Varma, V., Bodles, A.M., Rasouli, N., Unal, R., Phanavanh, B., Ranganathan, G., McGehee, R.E., Kern, P.A. J. Clin. Endocrinol. Metab. (2008) [Pubmed]
  35. Pioglitazone ameliorates tumor necrosis factor-alpha-induced insulin resistance by a mechanism independent of adipogenic activity of peroxisome proliferator--activated receptor-gamma. Iwata, M., Haruta, T., Usui, I., Takata, Y., Takano, A., Uno, T., Kawahara, J., Ueno, E., Sasaoka, T., Ishibashi, O., Kobayashi, M. Diabetes (2001) [Pubmed]
  36. Peroxisome proliferator-activated receptor-gamma ligands inhibit TGF-beta 1-induced fibronectin expression in glomerular mesangial cells. Guo, B., Koya, D., Isono, M., Sugimoto, T., Kashiwagi, A., Haneda, M. Diabetes (2004) [Pubmed]
  37. Expression of CD68 and macrophage chemoattractant protein-1 genes in human adipose and muscle tissues: association with cytokine expression, insulin resistance, and reduction by pioglitazone. Di Gregorio, G.B., Yao-Borengasser, A., Rasouli, N., Varma, V., Lu, T., Miles, L.M., Ranganathan, G., Peterson, C.A., McGehee, R.E., Kern, P.A. Diabetes (2005) [Pubmed]
  38. The peroxisome proliferator-activated receptor gamma agonist pioglitazone reduces the development of cartilage lesions in an experimental dog model of osteoarthritis: in vivo protective effects mediated through the inhibition of key signaling and catabolic pathways. Boileau, C., Martel-Pelletier, J., Fahmi, H., Mineau, F., Boily, M., Pelletier, J.P. Arthritis Rheum. (2007) [Pubmed]
  39. The effect of pioglitazone on hepatic glucose uptake measured with indirect and direct methods in alloxan-induced diabetic dogs. Matsuhisa, M., Shi, Z.Q., Wan, C., Lekas, M., Rodgers, C.D., Giacca, A., Kawamori, R., Vranic, M. Diabetes (1997) [Pubmed]
  40. Effect of pioglitazone on pancreatic beta-cell function and diabetes risk in Hispanic women with prior gestational diabetes. Xiang, A.H., Peters, R.K., Kjos, S.L., Marroquin, A., Goico, J., Ochoa, C., Kawakubo, M., Buchanan, T.A. Diabetes (2006) [Pubmed]
  41. Long-term effects on lipids and lipoproteins of pioglitazone versus gliclazide addition to metformin and pioglitazone versus metformin addition to sulphonylurea in the treatment of type 2 diabetes. Betteridge, D.J., Vergès, B. Diabetologia (2005) [Pubmed]
  42. A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Chiquette, E., Ramirez, G., Defronzo, R. Arch. Intern. Med. (2004) [Pubmed]
  43. Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study. Pfützner, A., Marx, N., Lübben, G., Langenfeld, M., Walcher, D., Konrad, T., Forst, T. J. Am. Coll. Cardiol. (2005) [Pubmed]
WikiGenes - Universities